Today Apidel announces the comppletion of a private placement, raising significant funds to accelerate and progress clinical and commercial development of its pipeline of therapeutic products. The press release is available here.
May marked Apidel’s fifth year in business! “Right from the start, the founders have had a long-term vision for the company and today we are all proud of our accomplishments. We have come a long way from a raw technology developed at the University of Geneva to a mature small company with a vision and an objective of developing a pipeline of exceptional pharmaceutical products. We have a world-class laboratory facility, along with our key manufacturing process under ISO standards. Several patents have been granted and a highly experienced team of dedicated people has been formed to further develop the company. All these steps, along with countless other achievements have been accomplished through the years to enable us to stand where we are today.
We believe that our success story will continue and all the planned milestones will be achieved in the near future, including the most important, the first clinical use of our technologies. With this in mind, we are going to continue to work hard to provide to patients the best in class pharmaceutical products. We are excited about the challenges to come!” Alan Cookson, CEO
The European Patent application No.10752926.5 “COMPOSITIONS COMPRISING POLYMERS PREPARED FROM 2-HYDROXYALKYL ACIDS” has been registered in the major European territories with the following patent number: EP2598553.
Apidel and The University of Geneva have been awarded a grant from the Swiss Commission for Technology and Innovation for a joint project entitled “Spironolactone-ApidSOL™ formulation for delayed healing of minor wounds in glucocorticoid treated patients”. Spironolactone is currently used only systemically to treat fluid retention. In this very innovative and highly promising project, Spironolactone will be formulated with ApidSOL™ technology to increase its bioavailability and therefore allow a topical application. Indeed, recent studies have demonstrated that Spironolactone could be a potential drug candidate for a number of indications in dermatology and ophthalmology.
Apidel, University of Geneva and HUG are proud to have been awarded a grant from the Swiss Commission for Technology and Innovation (CTI) to develop an optimized therapy for the inner ear conditions such as Menière’s disease or hearing loss. Our proprietary technologies ApidSOL™ and ApidCOR™ will be formulated with anti-inflammatory compound to be locally administered into the inner ear.
The European Patent Office has announced that it grants our European Patent application No. 10 752 926.5 “COMPOSITIONS COMPRISING POLYMERS PREPARED FROM 2-HYDROXYALKYL ACIDS”
A new publication mentioning our ApidSOL™ Technology has been published in the journal “Nanoscale”.
Lapteva et al, “Self-assembled polymeric nanocarriers for the targeted delivery of retinoic acid to the hair follicle”
A new publication mentioning Apidel’s ApidCOR™ Technology has been published:
Asmus et al, “Injectable formulations for an intravitreal sustained-release application of a novel single-chain VEGF antibody fragment”